VERISILICON
9.4.2024 09:01:28 CEST | Business Wire | Press release
VeriSilicon (688521.SH) today announced its demonstration at Embedded World 2024 in Nuremberg, Germany, booth numbered Hall 4A-518, where it is showcasing customers’ various leading products leveraging the company’s latest technologies and advanced solutions.
VeriSilicon’s one-stop custom silicon services and semiconductor IP licensing services provide customers with intelligent, secure, and highly adaptable solutions, addressing a wide range of key areas such as Artificial Intelligence (AI) and Machine Learning, Internet of Things (IoT), Consumer Electronics and Smart Devices, Data Center and High-Performance Computing, Smart Healthcare, and Automotive Electronics. Highlighted demonstrations include:
- AI and Machine Learning: A high-performance AI-PC with Blue Ocean’s chiplet acceleration card using GPGPU and NPU IPs powered by VeriSilicon, Google Open Se Cura powered by VeriSilicon, Inuitive vision AI processor featuring VeriSilicon’s dual-channel Image Signal Processor (ISP) IP.
- IoT: VeriSilicon’s LE Audio compliant complete Bluetooth Low Energy IP solution, LE Mesh system solution based on VeriSilicon’s BLE technology.
- Consumer Electronics and Smart Devices: A next-generation 8K TV and a leading Smart Camera integrated with VeriSilicon’s Neural Network Processor (NPU) IP, a next-generation Drone featuring VeriSilicon’s Video Processor Unit (VPU) IP, Smart Watches and Smart AR Glasses based on VeriSilicon’s Graphics Processor Unit (GPU) IP and Display Processor IP, Smart Home devices embedded with VeriSilicon’s IPs.
- Data Center and High-Performance Computing: VeriSilicon’s second-generation data center video transcoding platform solution.
- Smart Healthcare: VeriHealthi health monitoring platform based on VeriSilicon’s ZSP Digital Signal Processor (DSP) and BLE IPs.
- Automotive Electronics: Automotive SoC enabled by VeriSilicon’s ISO 26262 compliant IPs and subsystems.
VeriSilicon’s semiconductor IP licensing business holds the largest market share in China and ranks seventh worldwide1. Among the top ten IP companies globally, VeriSilicon’s number of IP categories ranks top two2. With over two decades of expertise in the GPU sector, VeriSilicon’s GPU IP has been shipped in nearly two billion chips. Additionally, VeriSilicon’s self-developed NPU IP has been integrated into 128 AI SoCs supplied by 72 licensees in more than 10 market segments, and has been shipped in over 100 million AI-enabled chips worldwide. In terms of video processing, VeriSilicon’s first-generation video transcoding acceleration solution, which is integrated with the company’s VPU IP, provides 6 times the transcoding capability of traditional high-end CPUs while consuming only 1/13 of the power. This innovative technology has been successfully applied to media accelerator chips custom-made for leading global chip companies based on the 5nm process and has entered the mass production stage.
As part of the Embedded World conference program, VeriSilicon’s Vice President of Vision Image Product Shang-Hung Lin will deliver a keynote speech themed Implementing Transformer Neural Networks for Visual Perception on Embedded Devices during Session 7.8 on Embedded Vision & Edge AI, scheduled for April 10 at 1:45pm.
“We are thrilled to present our latest and innovative IP solutions at Embedded World 2024. Our comprehensive Glass-to-Glass (from camera-in to display-out) intelligent pixel processing IP portfolio is silicon-proven, production-proven, and application-proven, which is configurable for a wide range of applications, ranging from low-power-focused to high-performance data center uses,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “In addition to our own IP offerings, we have also collaborated with third-party partners such as RISC-V IP providers and GUI software providers to deliver competitive solutions to our customers. Our commitment to IP innovations is aimed at empowering our customers’ success, enabling them to introduce innovative products to the market more quickly.”
To experience live demos and engage with VeriSilicon’s experts, please visit our booth at Messezentrum Nürnberg (Booth No.: Hall 4A-518) or schedule a meeting with us via email at eu-sales@verisilicon.com.
1 According to IPnest, April 2023
2 According to IPnest’s IP categorization and companies’ disclosure information
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409713011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom